Influence of prolonged exposure of a short half life non-steroidal anti-inflammatory drugs on gastrointestinal safety

被引：1
作者：
Campanella C. [1 ,2 ]
Jamali F. [1 ]
机构：
[1] Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton
[2] Biovail Contract Research, Toronto
来源：
Inflammopharmacology | 2009年 / 17卷 / 4期
基金：
加拿大健康研究院;
关键词：
Gastrointestinal side effect; Half-life; NSAID; Permeability;
D O I：
10.1007/s10787-009-0007-y
中图分类号：
学科分类号：
摘要：
Aims: To test the influence of frequent concentration peaking, as occurs in multiple-dosing of non-steroidal anti-inflammatory drugs (NSAIDs) with short t 1/2, and duration of therapy of NSAIDs on gastrointestinal permeability. Methodology: 2.5 mg/(kg 12 h) flurbiprofen was administered as repeated oral and interperitoneal (i.p) doses or as i.p. osmotic pump (once implanted to mimic long t 1/2) for 7 days to healthy rats. Urinary excretion of 51Cr-EDTA (days 0, 1, 4 and 7 during all regimens) and sucrose (days 0, 1 and 7 for i.p. doses) were measured as markers of gastroduodenal and intestinal permeability, respectively. Results: Both i.p. regimens elevated 51Cr-EDTA permeability suggestive of a systemic effect. There was no significant difference between the i.p regimens in 51Cr-EDTA permeability. The first day 51Cr-EDTA permeability was significantly higher for the oral than for the i.p. doses suggestive of a topcal effect. The effect became less potent with time despite continuous dosing indicating adaptation for both topical and systemic effects. None of the i.p. regimen altered sucrose permeability. Conclusion: NSAID's potency to increase permeability reduces with time despite continuous dosing. Topical effect following oral dosing, and not the frequent peaking differentiates regimens from each other in elevating 51Cr-EDTA permeability. The repeated dosing rather than the magnitude of t 1/2 may influence the gut safety profile of NSAIDs. © 2009 Birkhäuser Verlag.
引用
收藏
页码：205 / 210
页数：5
相关论文
共 36 条
  • [31] Schaffer D., Florin T., Eagle C., Et al., Risk of serious NSAID-related gastrointestinal events during long-term exposure: A systematic review, Med J Aust, 185, pp. 501-506, (2006)
  • [32] Silvani M.C., Motola D., Poluzzi E., Et al., Gastro-intestinal problems and concomitant medication in NSAID users: Additional findings from a questionnaire-based survey in Italy, Eur J Clin Pharmacol, 62, pp. 235-241, (2006)
  • [33] Silverstein F.E., Faich G., Goldstein J.L., Et al., Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study, JAMA, 284, pp. 1247-1255, (2000)
  • [34] Smecuol E., Bai J.C., Sugai E., Et al., Acute gastrointestinal permeability responses to different non-steroidal anti-inflammatory drugs, Gut, 49, pp. 650-655, (2001)
  • [35] St John D.J.B., Yeomans N.D., McDermott F.T., Et al., Adaptation of the gastric mucosa to repeated administration of aspirin in the rat, Am J Dig Dis, 18, pp. 881-887, (1973)
  • [36] Vakily M., Khorasheh F., Jamali F., Dependency of gastrointestinal toxicity on release rate of tiaprofenic acid: A novel pharmacokinetic-pharmacodynamic model, Pharm Res, 16, pp. 123-129, (1999)
1234